SYDNEY--(BUSINESS WIRE)--#Covid19--Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los Angeles, California.

�We are delighted to have dosed the first patient in the CEP-2 trial,� said City of Hope CEP-2 Principal Investigator Mark Agulnik, M.D. �The study investigates the use of Veyonda� in combination with the chemotherapy drug doxorubicin for first-line treatment of approximately 30 patients with soft tissue sarcoma, which is an aggressive cancer in urgent need of new treatment options.�

City of Hope, a world-renowned cancer center in the U.S., is the first site to commence treatment, but recruitment is ongoing and Noxopharm plans to open future major U.S. trial sites.

�Partnering with the prestigious City of Hope for this CEP-2 study, along with the MD Anderson Cancer Center and Beverly Hills Cancer Center for our radiation therapy trial [DARRT] program, represents the strength of our programs and the talent and experience of our team at Noxopharm,� said Noxopharm CEO and Managing Director Gisela Mautner, M.D.-Ph.D., MPH. �We look forward to adding additional prestigious study sites in the near future as we all work toward new treatment options.�

The first safety results for the CEP-2 study will be available after patient cohort 1 has completed the first cycle of combination therapy. The CEP-2 study is building on the CEP-1 study, which was a Phase 1a/1b trial that was published in April 2021 in the peer-reviewed journal Current Therapeutic Research, and showed the success of Veyonda in boosting the efficacy and safety of chemotherapy in late-stage cancer patients.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and inflammation. Veyonda� is the Company�s first pipe-line drug candidate currently in Phase 1 and 2 clinical trials.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of the US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases. To learn more, please visit: noxopharm.com.

Contacts

Lindsey Langemeier

SCORR Marketing

402-405-4269

[email protected]